Advertisement
Singapore markets open in 26 minutes

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • Dow

    38,675.68
    +449.98 (+1.18%)
     

  • Nasdaq

    16,156.33
    +315.33 (+1.99%)
     

  • Bitcoin USD

    64,225.72
    +332.61 (+0.52%)
     

  • CMC Crypto 200

    1,332.36
    +55.38 (+4.34%)
     

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • Gold

    2,301.70
    -6.90 (-0.30%)
     

  • Crude Oil

    78.09
    -0.02 (-0.03%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • Nikkei

    38,236.07
    -38.03 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.82 (+1.48%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    -7,117.42 (-49.94%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa Therapeutics, Inc.
·1-min read
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration. A video replay of the presentation will be available for 90 days following the event on the investor relations page of Atossa’s website: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com.

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com